Flagship Harbor Advisors’s BioCryst Pharmaceuticals BCRX Stock Holding History

Flagship Harbor Advisors’s Portfolio BCRX Stock Details BCRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-325	Closed	-$2.54K	–	861
2025 Q4	$2.54K	Buy	+325	New	+$2.35K	﹤0.01%	1806
2020 Q4	–	Sell	-300	Closed	-$1K	–	648
2020 Q3	$1K	Hold	300	–	–	﹤0.01%	1790
2020 Q2	$1K	Hold	300	–	–	﹤0.01%	1878
2020 Q1	$1K	Hold	300	–	–	﹤0.01%	1716
2019 Q4	$1K	Hold	300	–	–	﹤0.01%	1781
2019 Q3	$0	Hold	300	–	–	﹤0.01%	1838
2019 Q2	$1K	Hold	300	–	–	﹤0.01%	1749
2019 Q1	$2K	Hold	300	–	–	﹤0.01%	1654
2018 Q4	$2K	Hold	300	–	–	﹤0.01%	1619
2018 Q3	$2K	Hold	300	–	–	﹤0.01%	1886
2018 Q2	$1K	Buy	+300	New	+$1.65K	﹤0.01%	1920

Other funds holding BCRX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

TCM

TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return

Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return

Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return

VPC

Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return

Flagship Harbor Advisors's BCRX Position: Q1 2026 in Review

Flagship Harbor Advisors sold out of BioCryst Pharmaceuticals (BCRX) in Q1 2026, closing a stake of 325 shares — an estimated $2.54K sold.

Flagship Harbor Advisors first reported a position in BCRX in Q2 2018 and held it in 11 quarters. The position peaked at $2.54K in Q4 2025. 302 funds tracked by Wall St. Rank hold BCRX as of Q1 2026.

Flagship Harbor Advisors reported no remaining BioCryst Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
Flagship Harbor Advisors sold 325 BioCryst Pharmaceuticals shares in Q1 2026, an estimated $2.54K.
Flagship Harbor Advisors first reported a position in BioCryst Pharmaceuticals in Q2 2018 and held it in 11 quarters.
Flagship Harbor Advisors's BioCryst Pharmaceuticals position peaked at $2.54K in Q4 2025.
302 funds tracked by Wall St. Rank held BioCryst Pharmaceuticals as of Q1 2026.

Based on Flagship Harbor Advisors's 13F filing for Q1 2026, filed 28 Apr 2026.